Rigel Pharmaceuticals, Inc. (RIGL)

NASDAQ: RIGL · Real-Time Price · USD

46.48

-0.27 (-0.58%)

At close: Aug 26, 2026, 4:00 PM EDT

46.20

-0.28 (-0.60%)

After-hours: Aug 26, 2026, 7:30 PM EDT

Rigel Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	60.82	40.58	56.75	32.79	24.46	18.89
Short-Term Investments	34.51	114.38	20.58	24.15	33.75	106.08
Cash & Short-Term Investments	95.33	154.96	77.32	56.93	58.21	124.97
Cash Growth	-12.04%	100.41%	35.81%	-2.19%	-53.42%	117.99%
Receivables	56.04	51.76	41.62	30.55	40.32	15.47
Inventory	24.15	23.36	9.76	5.52	17.38	6.62
Prepaid Expenses	4.99	4.89	1.89	6.26	-	7.41
Other Current Assets	5.03	5.21	4.52	-	-	-
Total Current Assets	185.53	240.17	135.1	99.27	115.9	154.47
Property, Plant & Equipment	0.65	0.95	0.34	1.03	2.79	11.89
Other Intangible Assets	93.88	24.75	27.1	13.88	14.95	-
Long-Term Deferred Tax Assets	238.07	245.85	-	-	-	-
Other Long-Term Assets	2.94	1.88	1.44	3.06	0.64	0.97
Total Assets	521.07	513.59	163.98	117.23	134.28	167.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	4.01	7.19	3.34	7.14	22.51	3.8
Accrued Expenses	46.31	50.46	46.33	29.28	31.91	31.75
Current Portion of Long-Term Debt	39.24	29.81	7.27	10.87	3.94	7.97
Current Portion of Leases	0.66	0.61	0.29	0.69	1.13	9.89
Current Unearned Revenue	-	1.36	1.36	1.36	1.37	2.6
Other Current Liabilities	5.38	9.81	4.72	3.93	4.36	7.55
Total Current Liabilities	95.59	99.24	63.3	53.27	65.21	63.55
Long-Term Debt	-	22.48	92.39	92.32	81.71	72.64
Long-Term Leases	0.06	0.4	-	0.29	0.97	0.76
Other Long-Term Liabilities	-	-	5	-	-	-
Total Liabilities	95.64	122.11	160.69	145.87	147.9	136.95

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.02	0.02	0.02	0.02	0.17	0.17
Additional Paid-In Capital	1,423	1,414	1,393	1,379	1,369	1,354
Retained Earnings	-997.1	-1,023	-1,390	-1,408	-1,382	-1,324
Comprehensive Income & Other	-0.15	0.18	0.01	0.01	-0.15	-0.1
Shareholders' Equity	425.42	391.48	3.29	-28.64	-13.62	30.37
Total Liabilities & Equity	521.07	513.59	163.98	117.23	134.28	167.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	39.95	53.3	99.95	104.17	87.75	91.27
Net Cash (Debt)	55.38	101.65	-22.63	-47.23	-29.55	33.7
Net Cash Growth	16.99%	-	-	-	-	84.77%
Net Cash Per Share	2.83	5.40	-1.28	-2.71	-1.73	1.98
Filing Date Shares Outstanding	18.68	18.47	17.86	17.54	17.37	17.17
Total Common Shares Outstanding	18.65	18.31	17.71	17.48	17.34	17.16
Working Capital	89.94	140.93	71.8	46	50.69	90.91
Book Value Per Share	22.81	21.38	0.19	-1.64	-0.79	1.77
Tangible Book Value	331.54	366.73	-23.81	-42.52	-28.57	30.37
Tangible Book Value Per Share	17.77	20.03	-1.34	-2.43	-1.65	1.77
Machinery	-	-	-	1.83	9.48	16.04
Construction In Progress	-	-	-	-	-	0.69
Leasehold Improvements	-	-	-	-	2.11	-

SEC Filings: 10-K · 10-Q